| Literature DB >> 31443467 |
Ruby Celsia Arul Selvaraj1, Mala Rajendran2, Hari Prasath Nagaiah1.
Abstract
Biofilm-associated tissue and device infection is a major threat to therapy. The present work aims to potentiate β-lactam antibiotics with biologically synthesized copper oxide nanoparticles. The synergistic combination of amoxyclav with copper oxide nanoparticles was investigated by checkerboard assay and time-kill assay against bacteria isolated from a burn wound and a urinary catheter. The control of biofilm formation and extracellular polymeric substance production by the synergistic combination was quantified in well plate assay. The effect of copper oxide nanoparticles on the viability of human dermal fibroblasts was evaluated. The minimum inhibitory concentration and minimum bactericidal concentration of amoxyclav were 70 μg/mL and 140 μg/mL, respectively, against Proteus mirabilis and 50 μg/mL and 100 μg/mL, respectively, against Staphylococcus aureus. The synergistic combination of amoxyclav with copper oxide nanoparticles reduced the minimum inhibitory concentration of amoxyclav by 16-fold against P. mirabilis and 32-fold against S. aureus. Above 17.5 μg/mL, amoxyclav exhibited additive activity with copper oxide nanoparticles against P. mirabilis. The time-kill assay showed the efficacy of the synergistic combination on the complete inhibition of P. mirabilis and S. aureus within 20 h and 24 h, respectively, whereas amoxyclav and copper oxide nanoparticles did not inhibit P. mirabilis and S. aureus until 48 h. The synergistic combination of amoxyclav with copper oxide nanoparticles significantly reduced the biofilm formed by P. mirabilis and S. aureus by 85% and 93%, respectively. The concentration of proteins, carbohydrates, and DNA in extracellular polymeric substances of the biofilm was significantly reduced by the synergistic combination of amoxyclav and copper oxide nanoparticles. The fibroblast cells cultured in the presence of copper oxide nanoparticles showed normal morphology with 99.47% viability. No cytopathic effect was observed. Thus, the study demonstrated the re-potentiation of amoxyclav by copper oxide nanoparticles.Entities:
Keywords: Tamarindus indica; amoxyclav; burn wound; fibroblasts; urinary catheter
Mesh:
Substances:
Year: 2019 PMID: 31443467 PMCID: PMC6749510 DOI: 10.3390/molecules24173055
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Phylogenetic tree of the bacterial isolate. (a) Urinary catheter; (b) burn wound.
Antibiotic sensitivity profiles of bacteria.
| Diameter of Inhibition Zone (mm) | |||||||
|---|---|---|---|---|---|---|---|
| S. No | Bacteria | Amoxicillin | Amoxyclav | Cefixime | Ciprofloxacin | Gentamicin | Azithromycin |
| 1 |
| 5 ± 0.02 | 10 ± 0.05 | 11 ± 0.09 | 13 ± 1 | 25 ± 0.07 | 8 ± 0.04 |
| 2 |
| 3 ± 0.03 | 12 ± 0.08 | 12 ± 0.05 | 14 ± 0.06 | 28 ± 0.08 | 12 ± 0.07 |
Figure 2Synthesis and characterization of CuO NPs. (a) Formation of CuO NPs; (b) UV-Vis spectrum; (c) particle size distribution; (d) field emission scanning electron microscopic image (FESEM); (e) Fourier-transformed infrared spectrum (FTIR); (f) X-ray diffraction (XRD); (g) differential scanning calorimetry (DSC); (h) thermo gravimetric analysis (TGA).
Antibacterial activity of CuO NPs (diameter of inhibition zone in mm).
| Concentration of CuO NPs (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|
| S. No. | Bacteria | 5 | 10 | 15 | 20 | 25 | 30 |
| 1 |
| 5 | 10 ± 0.06 | 14 ± 0.08 | 16± 0.05 | 18 ± 1 | 24 ± 1 |
| 2 |
| 8 | 14 ± 0.07 | 18 ± 0.07 | 21± 0.09 | 24 ± 1 | 29 ± 1 |
| Concentration of T. indica fruit extract (30 μg/mL) | |||||||
| 1 |
| 10 ± 0.06 | |||||
| 2 |
| 16 ± 0.06 | |||||
Antibacterial activity of amoxyclav and CuO NPs.
|
|
| ||||||
|---|---|---|---|---|---|---|---|
| S. No. | Antibacterial Activity | Amoxyclav | CuO NP | Amoxyclav | CuO NP | ||
| 1 | MIC (μg/mL) | 70 | 30 | 1000 | 50 | 20 | 800 |
| 2 | MBC (μg/mL) | 140 | 60 | 4000 | 100 | 40 | 3200 |
Fractional inhibitory concentration index (FICI) of amoxyclav and CuO NPs.
|
| |||||
|---|---|---|---|---|---|
| Amoxyclav (μg/mL) | CuO NP | FIC of Amoxyclav | FIC of CuO NP | FICI | Interaction |
| 4.4 | 15 | 0.062 | 0.25 | 0.267 | Synergistic |
| 8.8 | 7.5 | 0.125 | 0.126 | 0.251 | Synergistic |
| 17.5 | 3.8 | 0.25 | 0.063 | 0.313 | Synergistic |
| 35 | 1.9 | 0.5 | 0.031 | 0.531 | Additive |
|
| |||||
| 1.56 | 10 | 0.03 | 0.5 | 0.503 | Additive |
| 3.15 | 5 | 0.06 | 0.25 | 0.31 | Synergistic |
| 6.25 | 2.5 | 0.12 | 0.125 | 0.225 | Synergistic |
| 12.5 | 1.25 | 0.24 | 0.06 | 0.31 | Synergistic |
Figure 3Synergy between amoxyclav and CuO NPs.
Figure 4Time-dependent destruction of bacteria by amoxyclav and CuO NPs on (a) P. mirabilis; and (b) S. aureus.
Figure 5Inhibition of biofilm formation by amoxyclav and CuO NPs.
Figure 6Inhibition of extracellular polymeric substance (EPS) formation by amoxyclav and CuO (a) P. mirabilis; and (b) S. aureus.
Impact of CuO NPs on viability of human dermal fibroblast cells.
| S. No. | Treatment | Viability (%) |
|---|---|---|
| 1 | Control | 100 |
| 2 | CuO NPs (30 μg/mL) | 99.47 |
Figure 7Effect of CuO NPs on the viability of human dermal fibroblasts: (a) control; (b) CuO NPs.
Figure 8Mechanism of CuO NPs synthesis.